FDA in ReverseFDA in Reverse

March 1, 2005

1 Min Read
MDDI logo in a gray background | MDDI

Originally Published MX March/April 2005

BUSINESS NEWS

In February, FDA reversed its earlier decision by approving the Vagus Nerve Stimulation (VNS) therapy system by Cyberonics (Houston) for the treatment of severe depression. The agency's approval permits the company to market the VNS system as a "long-term adjunctive treatment for patients over the age of 18 with chronic or recurrent treatment-resistant depression . . . that has not responded to at least four adequate antidepressant treatments."

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like